Morales-Ramirez JO, Teppler H, Kovacs C, et al. Antiretroviral effect of MK-0518, a novel HIV-1 integrase inhibitor, in ART-naïve HIV-1 infected patients. Program and abstracts of the 10th European AIDS Conference; November 17-20, 2005; Dublin, Ireland. Abstract LBPS1/6. Online summary: http://clinicaloptions.com/HIV/Conference%20Coverage/Dublin%202005/Capsules/LBPS1-6.aspx
Savarino A«A historical sketch of the discovery and development of HIV-1 integrase inhibitors».Expert Opin Investig Drugs,15,12,desembre 2006,p.1507–22. DOI: 10.1517/13543784.15.12.1507. PMID: 17107277.
Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD; Protocol 005 Team;Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial:http://www.ncbi.nlm.nih.gov/pubmed/17434401?dopt=Abstract
Savarino A«A historical sketch of the discovery and development of HIV-1 integrase inhibitors».Expert Opin Investig Drugs,15,12,desembre 2006,p.1507–22. DOI: 10.1517/13543784.15.12.1507. PMID: 17107277.
